Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $86,096.88 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,546 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $818,818.72. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Wednesday, October 30th, Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.30, for a total value of $57,542.40.
• On Monday, August 26th, Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.22, for a total value of $504,400.00.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $24.47 on Friday. The business’s 50 day moving average price is $24.22 and its 200-day moving average price is $20.26. Nurix Therapeutics, Inc. has a fifty-two week low of $4.96 and a fifty-two week high of $27.60. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -8.41 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NRIX. Driehaus Capital Management LLC purchased a new position in Nurix Therapeutics during the 2nd quarter worth $26,778,000. Redmile Group LLC increased its holdings in Nurix Therapeutics by 37.7% during the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock worth $65,900,000 after purchasing an additional 1,226,497 shares during the period. Samlyn Capital LLC purchased a new position in Nurix Therapeutics during the 2nd quarter worth $12,177,000. Ikarian Capital LLC purchased a new position in Nurix Therapeutics during the 1st quarter worth $4,410,000. Finally, Candriam S.C.A. increased its holdings in Nurix Therapeutics by 30.5% during the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock worth $24,297,000 after purchasing an additional 272,136 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NRIX. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a research note on Monday, October 21st. Stephens reissued an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research note on Monday, October 14th. Royal Bank of Canada dropped their price target on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Barclays increased their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Finally, Robert W. Baird began coverage on Nurix Therapeutics in a research note on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective for the company. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.